Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
HOLLYWOOD’S award season is in full swing – and it’s abundantly clear the super-skinny celebrity look is back with a ...
Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
A group representing compounding pharmacies has filed a lawsuit against the US Food and Drug Administration, arguing that the ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...
A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for removing semaglutide, the active ingredient in Ozempic, from its drug ...
Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.